Learn how to transform your clinical development with Quintiles' risk-based monitoring solution - Data-driven Trial Execution.

According to a 2016 study by the Tufts Center for the Study of Drug Development, for a single new drug, drug development costs can be $2.6B and take 10 years, with a significant portion of that cost attributed to trial operations.
Regulatory bodies have provided guidance on using risk-based monitoring to improve the operational efficiencies associated with clinical trial execution.

Technology advancements are delivering greater, and more timely, visibility into critical patient, site and study insights; enabling faster, more informed decisions throughout a study. Now, with Quintiles’ proven risk-based monitoring (RBM) approach, Data-driven Trial Execution, you can efficiently transform your clinical development efforts, using industry leading analytics with enhanced data review processes, to optimize trial management and resource allocation.